A research team led by Thor Ueland of Oslo University Hospital in Norway reports that activated leukocyte cell adhesion molecule (ALCAM) could be a potential biomarker for early identification of patients at increased risk of mortality from acute ischemic stroke. "Patients with high levels of ALCAM at admission of acute ischemic stroke displayed increased long-term mortality," states Ueland. "[Our findings] suggest that ALCAM [is] a reliable biomarker for clinical use."
展开▼
